Peak inspiratory flow through the Genuair® inhaler in patients with moderate or severe COPD

Respiratory Medicine

Volumn 103, Issue 12, 2009, Pages 1832-1837

  Magnussen, H ^a   Watz, H ^a   Zimmermann, I ^a   Macht, S ^a   Greguletz, R ^b   Falques, M ^c   Jarreta, D ^c   Garcia Gil, E ^c  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b Almirall Sofotec GmbH   (Germany)

^c R and D Centre ^*  (Spain)

Author keywords

Chronic obstructive pulmonary disease; Dry powder inhaler; Genuair inhaler; Peak inspiratory flow

Indexed keywords

ACLIDINIUM BROMIDE; PLACEBO;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DRY POWDER; FEMALE; HUMAN; MALE; PEAK INSPIRATORY FLOW; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, INHALATION; AGED; EQUIPMENT DESIGN; FEMALE; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; MUSCARINIC ANTAGONISTS; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TROPANES;

EID: 70350704823     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.07.006     Document Type: Article

References (13)

1. Lavorini F., Magnan A., Dubus J.C., et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med 102 (2008) 593-604
2. Feddah M.R., Brown K.F., Gipps E.M., and Davies N.M. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates. J Pharm Pharm Sci 3 (2000) 318-324
3. Smith K., Chan H., and Brown K. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J Aerosol Med 11 (1998) 231-245
4. Al Showair R.A., Tarsin W.Y., Assi K.H., Pearson S.B., and Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respir Med 101 (2007) 2395-2401
5. Janssens W., VandenBrande P., Hardeman E., et al. Inspiratory flow rates at different levels of resistance in elderly COPD patients. Eur Respir J 31 (2008) 78-83
6. Global Strategy for the Diagnosis. Management and prevention of COPD, global initiative for chronic obstructive lung disease [GOLD]. Available from: (2007). http://www.goldcopd.com
7. de Koning J.P., van der Mark ThW., Coenegracht P.M.J., Tromp ThFJ., and Frijlink H.W. Effect of an external resistance to airflow on the inspiratory flow curve. Int J Pharm 234 (2002) 257-266
8. Buist A.S., Vollmer W.M., and McBurnie M.A. Worldwide burden of COPD in high- and low-income countries. Part 1. The burden of obstructive lung disease (BOLD) initiative. J Tuberc Lung Dis 12 (2008) 703-708
9. Halbert R.J., Natoli J.L., and Gano A. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 28 (2006) 523-532
10. Srichana T., Martin G.P., and Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 7 (1998) 73-80
11. Chodosh S., Flanders J.S., Kesten S., Serby C.W., Hochrainer D., and Witek Jr. T.J. Effective delivery of particles with the handihaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med 14 (2001) 309-315
12. Newman S., Sutton D., Segarra R., Lamarca R., and de Miquel G. Lung deposition of aclidinium bromide from genuair, a multidose dry powder inhaler. Respiration (2009) Epub ahead of print
13. Brand P., Meyer T., and Weuthen T. Lung deposition of radiolabeled tiotropium in healthy subjects and patients with chronic obstructive pulmonary disease. J Clin Pharmacol 47 (2007) 1335-1341